(S)-α-[[(1,1-dimethylethoxy)carbonyl]amino]-3-quinolinepropanoic acid | 135101-20-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 英文名称: (S)-α-[[(1,1-dimethylethoxy)carbonyl]amino]-3-quinolinepropanoic acid
• 英文别名: (2S)-2-{[(tert-butoxy)carbonyl]amino}-3-(quinolin-3-yl)propanoic acid；(2S)-2-[(2-methylpropan-2-yl)oxycarbonylamino]-3-quinolin-3-ylpropanoic acid
• CAS: 135101-20-1
• 化学式: C₁₇H₂₀N₂O₄
• mdl: MFCD01632015
• 分子量: 316.357
• InChiKey: ZJIPRFVJGMPMPL-AWEZNQCLSA-N

物化性质

• 沸点：
  518.5±45.0 °C(Predicted)
• 密度：
  1.235±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.8
• 重原子数：
  23
• 可旋转键数：
  6
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.352
• 拓扑面积：
  88.5
• 氢给体数：
  2
• 氢受体数：
  5

安全信息

• 危险性防范说明：
  P261,P280,P301+P312,P302+P352,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H335

反应信息

• 作为反应物：
  描述：

  (S)-α-[[(1,1-dimethylethoxy)carbonyl]amino]-3-quinolinepropanoic acid 在 三苯基膦 、 偶氮二甲酸二乙酯 、 氯甲酸异丁酯 作用下， 以 四氢呋喃 、 N-甲基吡咯烷酮 为溶剂， 生成 [(S)-1-(5-Bromo-pyridin-3-yloxymethyl)-2-quinolin-3-yl-ethyl]-carbamic acid tert-butyl ester
  参考文献：
  名称：

  Identification of a novel 3,5-disubstituted pyridine as a potent, selective, and orally active inhibitor of Akt1 kinase

  摘要：

  Based on lead compounds 2 and 3 a series of 3,5-disubstituted pyridines have been designed and evaluated for inhibition of AKT/PKB. Modifications at the 3 position of the pyridine ring led to a number of potent compounds with improved physical properties, resulting in the identification of 11g as a promising, orally active Akt inhibitor. The synthesis, structure-activity relationship studies, and pharmacokinetic data are presented in this paper. (c) 2006 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2006.04.046
• 作为产物：
  描述：

  (9CI)-3-(氯甲基)-喹啉 在 盐酸 、 sodium hydroxide 、 sodium hydride 作用下， 以 1,4-二氧六环 、 乙醇 、 叔丁醇 为溶剂， 反应 15.0h， 生成 (S)-α-[[(1,1-dimethylethoxy)carbonyl]amino]-3-quinolinepropanoic acid
  参考文献：
  名称：

  Acosta, C. Kirk; Bahr, Martin L.; Burdett, James E., Journal of Chemical Research, Miniprint, 1991, # 5, p. 914 - 934

  摘要：

  DOI：

文献信息

• Tryptophan-derived butyrylcholinesterase inhibitors as promising leads against Alzheimer's disease
  作者：Anže Meden、Damijan Knez、Marko Jukič、Xavier Brazzolotto、Marija Gršič、Anja Pišlar、Abida Zahirović、Janko Kos、Florian Nachon、Jurij Svete、Stanislav Gobec、Uroš Grošelj

  DOI：10.1039/c9cc01330j

  日期：——

  Tryptophan-derived selective nanomolar butyrylcholinesterase inhibitors with great potential for symptomatic therapy against Alzheimer's disease are disclosed.

  色氮氨酸衍生的选择性纳摩尔丁酰胆碱酯酶抑制剂揭示了对抗阿尔茨海默病症状治疗具有巨大潜力。
• [EN] EFFLUX PUMP INHIBITORS<br/>[FR] INHIBITEURS DE POMPE D'ECOULEMENT
  申请人：MICROCIDE PHARMACEUTICALS, INC.

  公开号：WO1999037667A1

  公开（公告）日：1999-07-29

  (EN) Compounds are described which have efflux pump inhibitor activity. Also described are methods of using such efflux pump inhibitor compounds and pharmaceutical compositions which include such compounds.(FR) L'invention concerne des composés présentant une activité d'inhibiteur de pompe d'écoulement. L'invention concerne également des méthodes d'utilisation de ces composés inhibiteurs et des compositions pharmaceutiques renfermant de tels composés.

  （中文翻译）描述了具有外排泵抑制剂活性的化合物。还描述了使用这种外排泵抑制剂化合物的方法和包括这种化合物的药物组合物。
• Matrix Metalloproteinase Inhibitors:  A Structure−Activity Study
  作者：Daniel E. Levy、France Lapierre、Weisheng Liang、Wenqing Ye、Christopher W. Lange、Xiaoyuan Li、Damian Grobelny、Marie Casabonne、David Tyrrell、Kevin Holme、Alex Nadzan、Richard E. Galardy

  DOI：10.1021/jm970494j

  日期：1998.1.1

  Modifications around the dipeptide-mimetic core of a hydroxamic acid based matrix metalloproteinase inhibitor were studied. These variations incorporated a variety of natural, unnatural, and synthetic amino acids in addition to modifications of the P1' and P3' substituents. The results of this study indicate the following structural requirements: (1) Two key hydrogen bonds must be present between the enzyme and potent substrates. (2) Potent inhibitors must possess strong zinc-binding functionalities. (3) The potential importance of the hydrophobic group at position R3 as illustrated by its ability to impart greater relative potency against stromelysin when larger hydrophobic groups are used. (4) Requirements surrounding the nature of the amino acid appear to be more restrictive for stromelysin than for neutrophil collagenase, 72 kDa gelatinase, and 92 kDa gelatinase. These requirements may involve planar fused-ring aryl systems and possibly hydrogen-bonding capabilities.
• ACOSTA, C. KIRK;BAHR, MARTIN L.;BURDETT, JAMES E. (JR);CESSAC, JAMES W.;M+, J. CHEM. RES. (S) ,(1991) N, C. 110-111
  作者：ACOSTA, C. KIRK、BAHR, MARTIN L.、BURDETT, JAMES E. (JR)、CESSAC, JAMES W.、M+

  DOI：——

  日期：——
• US5128448A
  申请人：——

  公开号：US5128448A

  公开（公告）日：1992-07-07